---
mi_id: MIPR-node_50e5d1f
type: press_release
canonical_url: "https://www.pheonixresearch.com/healthcare/diagnostics/press-release/monopolised-test-11-33-per-cent-competitive-one-40-16-two-claims-of-first-place/"
md_url: "https://www.pheonixresearch.com/healthcare/diagnostics/press-release/monopolised-test-11-33-per-cent-competitive-one-40-16-two-claims-of-first-place.md"

schema:
  "@type": NewsArticle
  "@id": MIPR-node_50e5d1f
  url: "https://www.pheonixresearch.com/healthcare/diagnostics/press-release/monopolised-test-11-33-per-cent-competitive-one-40-16-two-claims-of-first-place/"
  title: The Monopolised Test Took an 11.33 Per Cent Cut and the Competitive One Took 40.16 — Two Vendors Claim First Place and Only One Claim Survives Its Own Footnote
  description: "Pheonix Research sizes haematology and coagulation diagnostics at USD 7,620 million in 2025, reaching USD 10,630 million by 2033 at 4.25 per cent — two markets, one closed reagent system, and two administered prices cutting at once."
  datePublished: "2026-11-15T13:03:27+00:00"
  dateModified: "2026-11-15T13:04:22+00:00"
  keywords:
    - haematology diagnostics market
    - coagulation diagnostics market
    - Sysmex
    - Werfen
    - Mindray
    - CMS clinical laboratory fee schedule
    - Anhui volume-based procurement
    - in vitro diagnostics
  isPartOf:
    - id: MISG-node_7e576db
      type: CollectionPage
      url: "https://www.pheonixresearch.com/healthcare/diagnostics/"
      name: Diagnostics
    - id: MIIN-node_50b4dbf
      type: CollectionPage
      url: "https://www.pheonixresearch.com/healthcare/"
      name: Healthcare
    - id: MIWS-root
      type: WebSite
      url: "https://www.pheonixresearch.com/"
      name: Pheonix Research

acf:
  phoenix_meta_title: The Monopolised Test Took an 11.33 Per Cent Cut and the Competitive One Took 40.16
  phoenix_meta_description: "Pheonix Research sizes haematology and coagulation diagnostics at USD 7,620 million in 2025, reaching USD 10,630 million by 2033 at 4.25 per cent — two markets, one closed reagent system, and two administered prices cutting at once."

global_schema:
  organization:
    "@id": MIWS-root#organization
    "@type": Organization
    url: "https://www.pheonixresearch.com/"
    name: Pheonix Research
  website:
    "@id": MIWS-root
    "@type": WebSite
    url: "https://www.pheonixresearch.com/"
    name: Pheonix Research
  api:
    "@id": MIWS-root#api
    "@type": WebAPI
    url: "https://www.pheonixresearch.com/"

graph:
  node_id: MIPR-node_50e5d1f
  graph_node_endpoint: "https://graph.pheonixresearch.com/api/v1/query/live/node/MIPR-node_50e5d1f"
  graph_snapshot: "https://graph.pheonixresearch.com/api/v1/read/live/graph"
  graph_exclusions: "https://graph.pheonixresearch.com/api/v1/read/live/exclusions"
  graph_meta: "https://graph.pheonixresearch.com/api/v1/read/live/meta"
  graph_bundle: "https://graph.pheonixresearch.com/api/v1/read/live/bundle"

discovery:
  discovery_json: "https://www.pheonixresearch.com/.well-known/pheonix-discovery.json"
  llms_txt: "https://www.pheonixresearch.com/llms.txt"
  sitemap: "https://www.pheonixresearch.com/sitemap.xml"
---
# The Monopolised Test Took an 11.33 Per Cent Cut and the Competitive One Took 40.16 — Two Vendors Claim First Place and Only One Claim Survives Its Own Footnote

Pheonix Research has published *Global Haematology and Coagulation Diagnostics Market Report, Size, Share and Forecast 2026-2033: Two Monopolies, One Tender*, which sizes the discipline at **USD 7,620 million in 2025**, reaching **USD 10,630 million by 2033** at a compound annual rate of **4.25 per cent** — **1.395 times** and **USD 3,010 million** of absolute growth, carried on reportable results rising from **4,180 million to 5,760 million** at 4.09 per cent. The full report is available at [pheonixresearch.com](https://www.pheonixresearch.com/healthcare/diagnostics/market-report/global-haematology-and-coagulation-diagnostics-market/).

The finding is that this is two markets wearing one name, and that the price of both was set by document rather than by competition. **87.72 per cent of the discipline’s value attributes to ten named pools, leaving a residual of 12.28 per cent** — against 48.9 per cent in clinical chemistry — because a six-part differential is produced by a closed system, in which the reagent, the optics, the algorithm that classifies a scattergram and the reference intervals a result is reported against come from one vendor and are validated together. No open chemistry channel exists here; a laboratory cannot buy a buffer from one supplier and a substrate from another. **Concentration and attributability are the same variable read from two ends, and a market with no unlisted middle is a market a procurement authority can see — and price.** A Chinese provincial tender in January 2023 and an American fee schedule in September 2026 did exactly that.

## The discipline that files the most results and sends the smallest invoice

A complete blood count is the most frequently ordered laboratory test in medicine and, per reportable result, one of the cheapest things a hospital buys. That combination — enormous volume, thin unit value — is why the assumptions normally applied to diagnostics break here. Measured against the **USD 104.9 billion** in vitro diagnostics base carried in the head report of this cluster, the discipline is **7.26 per cent of IVD value in 2025, falling to 6.45 per cent by 2033**. It is the only discipline in the cluster whose share of the market declines while its test volume grows faster than the market’s.

 | Indicator |  | 2025 |  | 2033 |  | Change |

 | Market value (USD m) |  | 7,620.0 |  | 10,630.0 |  | +3,010.0 |

 | CAGR, 2025–2033 |  | 4.25% (1.395x) |

 | Reportable results (million) |  | 4,180 |  | 5,760 |  | 4.09% CAGR |

 | Realised revenue per result (USD) |  | 1.823 |  | 1.845 |  | +0.15% CAGR |

 | Haematology field (USD m) |  | 4,350.0 (57.09%) |  | 5,643.0 (53.08%) |  | 3.31% CAGR |

 | Haemostasis field (USD m) |  | 3,270.0 (42.91%) |  | 4,988.0 (46.92%) |  | 5.42% CAGR |

 | Share of global IVD value |  | 7.26% |  | 6.45% |  | −0.82 pp |

 | Attributed to named vendors |  | 6,684.0 (87.72%) |  | Stated residual 936.0 (12.28%) |

## Two fields, moving in opposite directions inside one forecast

Haematology is **USD 4,350 million to USD 5,643 million at 3.31 per cent**. Haemostasis is **USD 3,270 million to USD 4,988 million at 5.42 per cent**. **Haemostasis therefore supplies USD 1,718 million of the discipline’s USD 3,010 million increment — 57.08 per cent of the growth from 42.91 per cent of the base.**

The inversion is in the volume, not the value. Haematology grows its reportable results faster — 4.17 per cent against 3.91 — and its revenue more slowly. That is the report’s central structural argument: **in haematology, volume is the problem, because volume is what gets tendered; in haemostasis, menu is the answer, because a D-dimer or an anti-Xa assay is a new line on a requisition rather than a cheaper version of an old one.**

Decomposed per result, the two fields pull in opposite directions and the total is their cancellation. Haematology falls from **USD 1.500 to USD 1.404** per reportable result — **−6.42 per cent** across the window, against clinical chemistry’s −10.3 per cent in the companion report. Haemostasis rises from **USD 2.555 to USD 2.867** — **+12.21 per cent** — as the mix shifts from PT and APTT toward D-dimer, anti-Xa and viscoelastic testing. Net across the discipline, revenue per result moves from **USD 1.823 to USD 1.845: +1.24 per cent over eight years, a 0.15 per cent CAGR.** Flat here is not stability. Flat is two contrary movements cancelling, and which one dominates after 2033 is a question about menu, not about demand.

## Two administered prices, and one of them does not name the test it cuts

Both price regimes were published, both are arithmetic, and they are not the same size.

 | Instrument |  | Measure |  | Value |

 | CMS CY 2027 CLFS, preliminary |  | Code 85025, complete blood count |  | USD 7.77 → 6.89 (−11.33%) |

 | CMS CY 2027 CLFS, preliminary |  | Medicare volume, code 85025 (2025) |  | 36 million tests |

 | CMS CY 2027 CLFS, preliminary |  | Cumulative vs 2018 weighted median |  | −35% |

 | CMS CY 2027 CLFS, preliminary |  | Codes with a lower weighted median |  | 1,171 of 1,528 |

 | CMS CY 2027 CLFS, preliminary |  | Estimated Medicare saving |  | ~USD 1 billion a year |

 | Anhui provincial alliance, January 2023 |  | Coagulation items, average combined reduction |  | 40.16% (22 bidders, 16 selected) |

 | Anhui provincial alliance, January 2023 |  | Coagulation items, maximum reduction |  | 49.59% |

There is a detail in the American publication that is specific to this report. CMS’s results-by-category table names six categories — clinical chemistry (387 codes, −16 per cent), molecular pathology (211, −22), genomic sequencing (42, −23), microbiology (224, −19.3), proprietary laboratory analysis (151, −2.4) and immunology (205, −19.3). **Haematology is not one of them.** The complete blood count — the second-highest-volume code in the entire schedule at 36 million Medicare tests a year — sits inside a category summary that does not name its own field. The largest-volume test in American medicine is priced in an accounting bucket.

The phase-in is the other half of the instrument. The Consolidated Appropriations Act, 2026 amended the statute so that no test may be cut more than **15 per cent a year from 2027 through 2029**. The American Clinical Laboratory Association’s reading of the preliminary file counted **775 tests taking the full 15 per cent in year one** and put the cumulative 2027–2029 reduction in Medicare Part B laboratory payments at about **USD 3.3 billion**, against a payment system of roughly USD 9 billion a year. A code facing a 35 per cent gap is not protected by a 15 per cent cap. It is scheduled.

The Chinese instrument attacks a different variable. Anhui province completed the country’s first volume-based procurement for coagulation reagents in January 2023, and the mechanism matters more than the headline: bidders self-declared products onto a provincial list; the ceiling was set not by a government formula but by **the volume-weighted average of what Anhui hospitals had actually paid on the provincial platform the previous year**; bidders competed on the size of their reduction against that ceiling; and **90 per cent of the prior year’s platform volume was committed as first-year purchase volume**. On the coagulation six: 22 bidders, 16 selected, **an average combined reduction of 40.16 per cent and a maximum of 49.59 per cent**. On the cardiac three: 26 bidders, 17 selected, an average of 57.35 per cent, a maximum of 80. Combined annual procurement savings were put at RMB 87.09 million.

That is not a negotiation. **It is a price discovery exercise in which the state obtains the disclosure the market had been withholding** — and it is why the monopolised test took the smaller cut. The American schedule reduced a code whose reagent nobody can substitute and whose vendor list is short. The Chinese tender reduced the reagent categories where a second and third supplier could bid.

## Two claims of first place, and only one survives its own footnote

Sysmex publishes two numbers that cannot both be right, and the gap is clean. Its *Integrated Report 2025* puts the global haematology field at **USD 4,300 million** (2024, own estimate) and its own share at **54.6 per cent, ranked first**. At 54.6 per cent of USD 4,300 million, Sysmex’s haematology revenue should be **USD 2,348 million**. Its disclosed haematology revenue for the year to March 2026 is JPY 299,407 million — **USD 2,023 million** at JPY 148/USD.

The shortfall is **USD 325 million, or 13.8 per cent**. Read it one way and the market is 13.8 per cent smaller than published (USD 3,705 million); read it the other and the share is 13.8 per cent lower than published (47.0 per cent). The two readings are arithmetically identical and neither can be dismissed. This report uses **USD 4,350 million** for 2025 haematology — the published figure rolled forward — and carries the 13.8 per cent as an explicit uncertainty band on the base rather than resolving it. **Any analyst quoting a haematology market size, including this one, is quoting a number whose only public derivation contradicts itself by 13.8 per cent.**

The same discipline applied to haemostasis produces a cleaner answer, and a smaller claim. Sysmex claims the number one position there as well, but its own footnote discloses that this ranking “includes sales through alliances” — its instruments reach the market substantially under the Siemens Healthineers brand. Its disclosed haemostasis revenue of **USD 489 million is 14.95 per cent of a USD 3,270 million field**, which cannot be a standalone first place. Werfen’s attributed **USD 1,200 million is 36.70 per cent**. On revenue, the haemostasis leader is Werfen, and the field’s leader holds barely more than a third of it.

**Haematology has a monopoly. Haemostasis does not.** That difference, and not product quality, is what the two price instruments are cutting — and it is the reason the haemostasis half of the discipline supplies 57.08 per cent of the growth while carrying 42.91 per cent of the base.

## The vendor disclosures sort by geography, not by product

Sysmex’s fiscal year to March 2026 is the cleanest natural experiment in the cluster. Group net sales fell 1.7 per cent to **JPY 500,006 million**, operating profit fell **40.8 per cent** to JPY 51,831 million, and operating margin collapsed from **17.2 per cent to 10.4 per cent**. Inside that: **China −24.2 per cent, Japan −13.5, the Americas +6.2, EMEA +12.6.** Same products, same reagents, same service model. The company attributes the China decline to “policies to curtail medical expenses,” naming haematology instruments and reagents as well as haemostasis reagents. Its overseas haemostasis reagent sales fell while overseas haematology reagent sales rose — same reagent categories, different tender coverage.

Werfen gives the counter-reading. Europe’s haemostasis specialist grew **3.3 per cent organically to EUR 2,131 million**; excluding Asia, organically **6 per cent**, with North America up 8, Latin America up 10 and Eastern Europe, Middle East and Africa up 7. **Asia-Pacific fell 10.9 per cent.** EBITDA was EUR 473 million. Again, not the product. The market.

Mindray is the important one, because volume-based procurement is designed to favour domestic scale and Mindray grew share inside it. International revenue rose **7.40 per cent to RMB 17,650 million** while domestic revenue fell **22.97 per cent to RMB 15,632 million**; the IVD line fell 9.41 per cent to RMB 12,241 million. The company names immunoassay, chemistry and coagulation as the three core businesses in which it intends to double domestic share within three years — a target that only makes sense if the price reset also cleared out competitors. **The discipline is not losing China. It is losing the China price.** Those are different forecasts.

## The analyser is placed; the reagent is the annuity

Reagents, controls and calibrators are **66.8 per cent of the market in 2025 and 68.9 per cent by 2033**. Instruments are 20.9 per cent, falling to 19.0. That ratio is the whole commercial logic, and Werfen states it without ornament: capital sales of analysers drive “an installed base of recurring high-margin reagent and consumable revenue.”

Which is why the two price instruments above are not equivalent events. A reagent tender is a cut to the vendor’s revenue line on equipment that is already on the bench and already paid for, and the invoice a hospital sends its payor is a different number computed on a different schedule. The vendor cannot decline the price and cannot remove the analyser. Sysmex took 1.7 per cent off group sales and 40.8 per cent off operating profit in one year: the consequence of an administered cut lands on the reagent line, while the capital is already committed and cannot be withdrawn.

## Four scenarios, two variables, and neither of them is technology

 | Scenario |  | 2033 value (USD m) |  | CAGR |  | Condition |

 | Downside — China stays depressed two more years |  | 10,180 |  | 3.69% |  | Further provincial rounds in 2026–2027 before stabilisation |

 | **Base** |  | **10,630** |  | **4.25%** |  | China stabilises from 2027; US schedule absorbed at the 15% annual cap |

 | China normalisation |  | 11,020 |  | 4.72% |  | Tender anniversary effect rolls off; volume recovery faster than assumed |

 | Upside — haemostasis menu accelerates |  | 11,140 |  | 4.86% |  | Anti-Xa and DOAC monitoring, viscoelastic testing and perioperative pathways lift haemostasis to 6.5% |

The asymmetry is 56 basis points below base and 61 above, and that narrowness is the point. **This discipline’s forecast is not sensitive to technology adoption or to a single product cycle. It is sensitive to whether two governments continue to cut administered prices, and to nothing else at comparable magnitude.** The path is also not straight, for reasons of timing rather than trend: 2026 carries the full anniversary of the Chinese reset with no offsetting recovery, 2027 is the first year the American schedule cut lands, and the slight acceleration in 2032–2033 reflects the point at which the tendered base has been reset low enough that further cuts stop producing savings.

## Scope and method

In scope: automated haematology analysers and their reagents, controls and calibrators, from three-part through six-part differential, reticulocyte and body-fluid modes and digital morphology; automated and semi-automated coagulation analysers and their reagents, from routine screening through D-dimer, antithrombin and anti-Xa, thrombophilia and factor assays, von Willebrand and platelet-function testing and heparin-induced thrombocytopenia; and point-of-care haemostasis testing. Out of scope and deliberately adjacent rather than counted: blood gas and electrolyte testing, transfusion immunohematology and donor screening, flow cytometry as a standalone instrument category, molecular haematology — BCR-ABL, JAK2, NPM1 — which belongs to the molecular cluster, and haemostasis pharmaceuticals.

The report is built on a **70 per cent secondary and 30 per cent primary** basis. The secondary layer is audited annual results, statutory fee schedules, provincial procurement notices and regulatory filings, read directly rather than summarised. The primary programme comprised **47 depth interviews across 13 markets** with laboratory directors, haematology section leads, transfusion service managers, procurement officers and IVD channel partners; **29 open-ended interviews conducted around tender cycles** in the Chinese provincial and Gulf Cooperation Council procurement markets; a **176-respondent structured survey** of laboratory managers on analyser replacement intent, menu expansion and reagent price expectations; and structured observation at four conferences — the International Society on Thrombosis and Haemostasis congress, the International Society for Laboratory Hematology symposium, the American Association for Clinical Chemistry annual meeting and the Chinese Laboratory Medicine Congress. **No primary interview or survey response carries a figure.** Where a published participant estimate and a disclosed revenue contradict each other, both are shown and the contradiction is stated rather than resolved. Currency basis is JPY 148, EUR 1.13 and RMB 7.20 per USD throughout, consistent with every other report in this cluster. The report contains no third-party market-research citations.

## Companion analysis

- The Complete Blood Count Is the Second-Most-Ordered Test in America and Its Category Does Not Exist — the preliminary CY 2027 fee schedule, and why haematology has no category in CMS’s own results table.

- Sysmex’s Own Numbers Disagree by Thirteen Point Eight Per Cent on the Size of the Market It Leads — the reconciliation in full, and what an unresolved 13.8 per cent does to a base.

- Haemostasis Is Forty-Three Per Cent of This Discipline and Fifty-Seven Per Cent of Its Growth — why the field that is 42.91 per cent of the value supplies 57.08 per cent of the increment.

- Mindray Grew Share in a Market That Fell Twenty-Three Per Cent — the Anhui procurement mechanism in full, and why this discipline is losing the China price rather than China.

## About this report

The full report — with market definition and scope, executive summary, market size and forecast, base construction and revenue attribution, the two administered price instruments, regional structure, product and technology structure, end-market structure, forecast and sensitivities, competitive landscape, competitive snapshot and vendor evidence, value chain and margin structure, technology and innovation, investment activity, market risk, regulatory and policy environment, and research methodology and sources — is available at [https://www.pheonixresearch.com/healthcare/diagnostics/market-report/global-haematology-and-coagulation-diagnostics-market/](https://www.pheonixresearch.com/healthcare/diagnostics/market-report/global-haematology-and-coagulation-diagnostics-market/).

## About Pheonix Research

Pheonix Research is a market intelligence platform that queries a live graph of more than 500 nodes across 25 industrial sectors to surface leading signals and translate them into role-specific decisions. Its premise is that companies operate in value chains rather than industries, and that a signal is only useful when it arrives with the context and the window to act on it.
